Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

Jan 04, 2018
Source URL: https://qa1.novartis.us/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-drug-promacta-receives-fda-breakthrough-therapy-designation-first-line-use-severe-aplastic-anemia-saa-0